Dear NCCN Guidelines Panel for Non-Small Cell Lung Cancer,

**Request:**
- Please consider the results of the double-blind, placebo-controlled, Phase 3 IMpower132 trial designed to evaluate Tecentriq® (atezolizumab) plus carboplatin or cisplatin and pemetrexed for the first-line treatment of patients with metastatic non-squamous non-small cell lung cancer (NSCLC).

**Rationale:**
- At a median follow-up of 14.8 months, Tecentriq plus carboplatin or cisplatin and pemetrexed met the co-primary endpoint of investigator-assessed progression-free survival compared to carboplatin or cisplatin plus pemetrexed in the first-line treatment of patients with metastatic non-squamous NSCLC without EGFR or ALK genetic alteration. Interim overall survival (OS) data showed numerical improvement, but was not statistically significant and the next OS analysis is anticipated in the first half of 2019.
- The safety profile of Tecentriq plus carboplatin or cisplatin and pemetrexed was consistent with the known safety risks of the individual medicines with no new signals observed.

**FDA Clearance:**
- Tecentriq plus carboplatin or cisplatin and pemetrexed is not FDA-approved for the treatment of patients with metastatic non-squamous NSCLC. Please refer to the product prescribing information for the full FDA-approved indications and safety information, available at: [https://www.gene.com/medical-professionals/medicines/tecentriq](https://www.gene.com/medical-professionals/medicines/tecentriq)

Any references supplied to you are protected under U.S. Copyright Law (Title 17, U.S. Code). No further reproduction is permitted.

Thank you for your consideration and I hope this information is helpful to you. If you have any questions, please contact us at the phone number and email provided above.

Respectfully submitted,
Jordana Wollmann, PharmD

**References**